ClinicalTrials.gg
Active, not recruitingNCT05460767Updated Aug 25, 2026

Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

A Phase 1 interventional study of IBI363 and Bevacizumab in Solid Tumors or Lymphoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
504
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 276 studies in Lymphoma with a site in China — 103 open to participants now, 119 under way, 10 of them phase 3. Lymphoma · China.

Enrollment
7th of 232
504 · median 47
Started
2022
with 35 others
Phase 1
83 of 276
25 open now
Primary completion
2026-12
later than 56 of 118 live
Registered
160th of 276
by date

Among the 276 studies in Lymphoma with a site in China, this one is the 7th largest by enrollment of the 232 interventional ones that give a count, is one of 36 that started in 2022, is one of 83 in phase 1, reaches primary completion later than 56 of the 118 other live ones, and was the 160th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

103 of the 276 studies in Lymphoma with a site in China are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Lymphoma with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, multicenter, phase Ia/Ib study. The study will evaluate the safety, tolerability and preliminary efficacy of IBI363 in subjects with advanced, relapsed or metastatic solid tumors or lymphoma, determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and thus determine the recommended phase 2 dose (RP2D).

Read the detailed description

This study is an open-label, multicenter, phase Ia/Ib study. The study will evaluate the safety, tolerability and preliminary efficacy of IBI363 in subjects with advanced, relapsed or metastatic solid tumors or lymphoma, determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and thus determine the recommended phase 2 dose (RP2D). The phase Ia part consists of the dose escalation and PD marker exploration part. The phase Ib part consists of the dose expansion part.

03

Conditions studied

  • Solid Tumors or Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, ≥ 18 years
  2. or cytologically confirmed, unresectable locally advanced or solid tumors or lymphomas
  3. Subjects who progressed or are intolerant to existing standard therapy or subjects without standard therapy Note: Subjects may have received and failed prior therapy with a /PD-L1 inhibitor and be considered eligible for this trial.
  4. Subjects with at least one according to v1.1 for solid tumor or Lugano 2014 for lymphoma
  5. performance status (ECOG PS) of 0 or 1.
  6. Expected survival time ≥ 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with history of or known active seizure disorder, , spinal cord compression, or carcinomatous meningitis, or new evidence of brain or .
  2. Subjects with active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to first administration of study drug unless adequately treated and considered by the Investigator to be stable.
  3. Active uncontrolled bleeding or a known bleeding diathesis.
  4. Subjects with massive pleural effusion or massive ascites.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
504 participants (actual)

Study arms

  • Experimental
    IBI363

    Arm 1

    Biological: IBI363

  • Experimental
    IBI363+Bevacizumab

    Arm 2

    Biological: IBI363 · Drug: Bevacizumab

Interventions

  • BiologicalIBI363

    a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.

  • Recombinant humanized monoclonal antibody against vascular endothelial growth factor

06

What researchers measure

Primary outcomes

  1. Number of dose-limiting toxicity (DLT)

    Incidence of dose-limiting toxicity (DLT) events

    Time frame: 21 days during the first 3-week cycle

  2. incidence of adverse events (AE), serious adverse events (SAEs), treatment-emergent AEs (TEAEs) and immune-related AEs (irAEs)

    AE is defined as an medical problem that happens during treatment with a drug or other therapy. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. A TEAE will be defined as any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered. irAEs will be assessed.

    Time frame: up to 90 days after the last administration

  3. Number of participants with abnormality in vital signs

    Blood pressure, pulse, respiratory rate, and temperature will be assessed.

    Time frame: up to 90 days after the last administration

  4. Number of participants with abnormality in hematology parameters

    Blood samples will be collected to evaluate hemoglobin, white blood cell (WBC) count, platelets and coagulation factors including international normalized ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT)

    Time frame: up to 90 days after the last administration

  5. Number of participants with abnormality in clinical chemistry parameters

    Blood samples will be collected to evaluate sodium, potassium, calcium, magnesium, chloride, glucose, creatinine, urea or blood urea nitrogen (BUN), bicarbonate, amylase, bilirubin, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total protein, albumin, lactate dehydrogenase and lipase.

    Time frame: up to 90 days after the last administration

  6. Number of participants with abnormality in routine urinalysis parameters

    Urine samples will be collected to evaluate specific gravity, leucocyte esterase, nitrite, blood, bilirubin, protein, glucose, ketones and urobilinogen.

    Time frame: up to 90 days after the last administration

  7. Number of participants with abnormality in ECG parameters

    12-lead ECG will be obtained using an ECG machine. Participants will be in supine or a semi-recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs are recorded.

    Time frame: up to 90 days after the last administration

Secondary outcomes

  1. maximum concentration (Cmax)

    PK parameters to be evaluated for IBI363 including maximum concentration (Cmax) will be determined when appropriate.

    Time frame: Up to 2 years

  2. area under the curve (AUC)

    PK parameters to be evaluated for IBI363 including area under the curve (AUC) will be determined when appropriate.

    Time frame: Up to 2 years

  3. clearance (CL)

    PK parameters to be evaluated for IBI363 including clearance (CL) will be determined when appropriate.

    Time frame: Up to 2 years

  4. half-life (t1/2) of IBI363

    PK parameters to be evaluated for IBI363 including half-life (t1/2) will be determined when appropriate.

    Time frame: Up to 2 years

  5. volume of distribution (V)

    PK parameters to be evaluated for IBI363 including volume of distribution (V) will be determined when appropriate.

    Time frame: Up to 2 years

  6. Objective response rate (ORR)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  7. time to response (TTR)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  8. duration of response (DoR)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  9. disease control rate (DCR)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  10. progression-free survival (PFS)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  11. 6-month and 1-year PFS rate

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  12. Overall survival (OS)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: through study completion, an average of 1 year

  13. 6-month and 1-year OS rate

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  14. The incidence of ADA and NAb of IBI363

    Each subject will be tested for anti-drug (IBI363) antibody (ADA), and ADA-positive serum samples will continue to be tested for neutralizing antibodies (NAb).

    Time frame: Up to 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 52 months is above that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2022
First posted
Jul 15, 2022
StartActual
Aug 31, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05460767
Responsible party
Sponsor
First posted
Jul 15, 2022
Start date
Aug 31, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363

Start the discussion